JAK2 and acute lymphoblastic leukemia: However, high CRLF2 levels and increased activation of JAK2 sufficiently activate wild-type KRAS in 80% of DL-ALL cases, suggesting that therapeutics inhibiting overstimulated KRAS are needed [17].